DARWIN EU delivers real-world evidence across Europe diseases, population us performance medicines. enables EMA national competent authority European medicine regulatory network use data whenever needed throughout lifecycle medicinal product. Data Home (EMA) established coordination centre provide timely reliable evidence use, safety effectiveness medicine human use, including vaccines, real world healthcare database across European Union (EU).This capability called Data Analysis Real World Interrogation Network (DARWIN EU). Expression Interest Call open Data Partners. information found . Latest News European Health Data Space DARWIN EU connect European medicine regulatory network European Commission's European Health join data network? Open Call DPs described document welcome expression interest data custodian Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting DARWIN EU deliver? DARWIN EU delivers real-world evidence across Europe diseases, population us performance medicines. enables EMA use data whenever needed throughout lifecycle . DARWIN EU support regulatory decision-making by: establishing expanding catalogue observational data source use medicine regulation; providing source high-quality, validated real world data uses, safety medicines; addressing specific question carrying high-quality, non-interventional studies, including developing scientific protocols, interrogating relevant data source interpreting reporting study results. range approved healthcare database enabling distributed data access via DARWIN EU evolve expand time. former HMA/EMA Big Data Task Force originally recommended developing DARWIN EU. creation DARWIN EU feature EMA-HMA Big Data Steering Group workplan European medicine agency network strategy 2025. information: Timelines February 2022, EMA selected service provider (Erasmus University Medical Center Rotterdam) deliver DARWIN EU, following call tender. 2022 2023, service provider will: set DARWIN EU's operational process governance structures; run study data DARWIN EU, support EMA scientific committee down-stream decision-makers decision-making support establishment EHDS. 2024, EMA expects DARWIN EU fully operational. stage, DARWIN EU routinely support evaluation work EMA's scientific committee . Organisations , payer may make use DARWIN EU longer term. Figure 1: Overview DARWIN EU timeline 2021 Project initiation Select service provider deliver DARWIN EUCoordination Centre Establish DARWIN EU Advisory Board Support EDHS pilot 2022 DARWIN EU establishment Define governance structures, contract model process Run early study support EMA committee Provide first catalogue real world data source standard analysis Establish connectivity EHDS 2023 Developing using DARWIN EU Launch publicly-available DARWIN EU website Work established data permit authority Test business process access analyse healthcare data Run study support EMA committee 2024 Full operation mode Conduct study answer question support EMA scientific committee DARWIN EUfully operational involvement data partner medicine regulator 2025 Leverage EU Health Data Space Increase geographical coverage, scope regulatory us healthcare data DARWIN EU Related content External link Related document List item First published: 12/03/2021 EMA/48625/2021 List item First published: 20/01/2020 EMA/520966/2019 List item First published: 21/12/2020 Last Updated: 15 December 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Home (EMA) established coordination centre provide timely reliable evidence use, safety effectiveness medicine human use, including vaccines, real world healthcare database across European Union (EU).This capability called Data Analysis Real World Interrogation Network (DARWIN EU). Expression Interest Call open Data Partners. information found . Latest News European Health Data Space DARWIN EU connect European medicine regulatory network European Commission's European Health join data network? Open Call DPs described document welcome expression interest data custodian Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting DARWIN EU deliver? DARWIN EU delivers real-world evidence across Europe diseases, population us performance medicines. enables EMA use data whenever needed throughout lifecycle . DARWIN EU support regulatory decision-making by: establishing expanding catalogue observational data source use medicine regulation; providing source high-quality, validated real world data uses, safety medicines; addressing specific question carrying high-quality, non-interventional studies, including developing scientific protocols, interrogating relevant data source interpreting reporting study results. range approved healthcare database enabling distributed data access via DARWIN EU evolve expand time. former HMA/EMA Big Data Task Force originally recommended developing DARWIN EU. creation DARWIN EU feature EMA-HMA Big Data Steering Group workplan European medicine agency network strategy 2025. information: Timelines February 2022, EMA selected service provider (Erasmus University Medical Center Rotterdam) deliver DARWIN EU, following call tender. 2022 2023, service provider will: set DARWIN EU's operational process governance structures; run study data DARWIN EU, support EMA scientific committee down-stream decision-makers decision-making support establishment EHDS. 2024, EMA expects DARWIN EU fully operational. stage, DARWIN EU routinely support evaluation work EMA's scientific committee . Organisations , payer may make use DARWIN EU longer term. Figure 1: Overview DARWIN EU timeline 2021 Project initiation Select service provider deliver DARWIN EUCoordination Centre Establish DARWIN EU Advisory Board Support EDHS pilot 2022 DARWIN EU establishment Define governance structures, contract model process Run early study support EMA committee Provide first catalogue real world data source standard analysis Establish connectivity EHDS 2023 Developing using DARWIN EU Launch publicly-available DARWIN EU website Work established data permit authority Test business process access analyse healthcare data Run study support EMA committee 2024 Full operation mode Conduct study answer question support EMA scientific committee DARWIN EUfully operational involvement data partner medicine regulator 2025 Leverage EU Health Data Space Increase geographical coverage, scope regulatory us healthcare data DARWIN EU Related content External link Related document List item First published: 12/03/2021 EMA/48625/2021 List item First published: 20/01/2020 EMA/520966/2019 List item First published: 21/12/2020 Last Updated: 15 December 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutWho Involved? involved? DARWIN EU ha multiple actors: , , , . Data Partners DARWIN EU collaborates data partner help generate real-world evidence used scientific evaluation regulatory decision-making. Data partner partner access raw data in-house remotely, ownership, public contract, third-party agreement commercial license. Data partner enable DARWIN EU use data scientific study executing analytic packages, provide analysis result DARWIN EU Coordination Centre, accordance data protection governancerules. information see page. Coordination Centre ha key function DARWIN EU. CC provides structure developing managing network data partners, including training process study methods, evaluating eligibility performing studies, monitoring data quality. CC also responsible implementing operating step , feasibility request study final delivery study report EMA, result integrated within EU regulatory decision making process. addition, Coordination Centre responsible methodological development DARWIN EU, directed instructed EMA, interact relevant initiatives. Erasmus University Medical Center Rotterdam wa selected contractor public tendering procedure published June 2021 setup Coordination Centre EMA. information see page. European Medicines Agency responsible providing leadership direction, setting standard DARWIN EU, contracting, instructing overseeing Coordination Centre monitoring performance. question raised EU Medicines Regulatory Network requiring additional evidence support regulatory decision-making, EMA coordinate definition research question define, requesting body, study objective possible study design option study population, exposures, outcome statistical measures. information communicated Cordination Centre feasibility assessment. Based feasibility assessment, EMA, consultation Cordination Centre, decide relevance conducting study, specify eligibility criterion database included, identify relevant database define evidentiary standard applied study (e.g., data quality). EMA process result analysis report specific studies, feeding result decision-making, appropriate. support establishment DARWIN EU, ha set EMA. EU Medicines Regulatory Network EU Medicines Regulatory Network includes EMA (encompassing scientific committee working parties), national competent authority (NCAs) Member States European Economic Area (EEA) European Commission. operation DARWIN EU, need additional real-world evidence identified within EU Medicines Regulatory Network support regulatory activity submitted discussed EMA. Organisations Interactions EMA organisations, institution project take place improve infrastructure, methodological standard operational process DARWIN EU network. interaction could take place with, example: (EHDS), DARWIN EU key user need fully integrated use service provided EHDS; ongoing EU national project scope DARWIN EU relevant quality, transformation, maintenance analysis real-world datasets, including European networking initiative (EHDEN) project, European platform registry European Reference Networks (ERNs), ha established registry platform rare diseases; (ENCePP) network, integration continuously updating good methodological practice pharmacoepidemiology, identification data source registration studies; regulatory authority third countries, learn experience integrate learning governance methodological aspects. Last Updated: 26 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutCoordination Centre Coordination Centre EMA working Erasmus University Medical Center Rotterdam to: establish theDARWIN EUCoordination Centre, support work build distributed data network; conduct scientific study answer research question supporting regulatory decision-making EMA's scientific committee ; maintain catalogue real world data source use regulatory context metadata. DARWIN EU Coordination Centre key user future . contract establish Coordination Centre wa awarded Erasmus University Medical Center Rotterdam following call tender service provider published June 2021. group Department Medical Informatics leading Establishment Operational Phase DARWIN EU Coordination Centre. Organisational Structure DARWIN EU CC exists run study within data partner network, overseen Study Network Operations pillars, respectively. pillar able execute study onboard Data Partners using tool (such code protocols) created Development pillar within infrastructure ha created Technology pillar. Technology pillar also responsible producing necessary project resources, website service desk. overall operation DARWIN EU overseen Management pillar guidance Advisory Boards. Leadership Erasmus MC Executive Director Technology Pillar Lead Erasmus MC, Oxford University Deputy Director Development Pillar Lead Erasmus MC Deputy Director Study Operations Pillar Lead Synapse Research Management Partners Management Pillar Lead Erasmus MC Network Operations Pillar Lead Additional Members core team , Development Pillar Co-lead , MSc, Analytics Team Co-lead , Study Operations Co-lead , Technology Pillar Co-lead , Management Pillar Co-lead , Management Team Lead addition, large team data scientists, epidemiologist programmer working Coordination Centre Erasmus MC subcontractors. Contributing Organisations Organisation: Department Medical Informatics, Erasmus MC Description: Erasmus University Medical Center largest eight university medical center Netherlands. Department Medical Informatics, chaired Prof. dr. ir. Peter Rijnbeek, interdisciplinary research group within Erasmus MC study new method acquiring, representing, processing, managing data knowledge health care biomedical science ha developed land marking infrastructure software distributed analysis electronic health records. Health Data Science research line Prof. Rijnbeek leading , (EHDEN). mission group produce clinically actionable insight observational health data enabling data-driven healthcare. Improved interoperability data necessary pre-requisite mission. Learn Organisation: Clinical Investigation Translational Science, NDORMS, University Oxford Description: Clinical Investigation Translational Science division Botnar Research Centre (NDORMS, University Oxford) includes Clinical Trial Design Medical Statistics Health Data Science sections. Health Data Science section, led Prof Daniel Prieto-Alhambra, includes multidisciplinary team 30 staff student expertise data sciences, engineering, epidemiology, real world evidence. Learn at: Organisation: Synapse Research Management Partners Description: Synapse firm specialized high quality management complex research development project biomedical sector. Synapse partner national international organisations, public private (pharmaceutical biotechnology companies, research institutes, academia, hospitals, etc.). Synapse ha track record research project highly innovative (open innovation, public private partnerships), large (with several million Euros funding), distributed (built collaboration several institutions) internationally oriented (with broad expertise project funded European Commission). Learn . Organisation: Description: IQVIA leading global provider advanced analytics, technology solutions, clinical research service health sector across globe. IQVIA creates intelligent connection across aspect healthcare analytics, transformative technology, big data resource extensive domain expertise. IQVIA delivers powerful insight speed agility enabling life science industry customer accelerate clinical development commercialization innovative medical treatment enabling government ass improve public health population management, leading improved patient outcomes. approximately 86,000 employees, IQVIA conduct operation 100 countries. Learn . Organisation: Hyve Description: Hyve company provides professional service open source software. specialize field cancer genomics, translational data warehousing, real world data analytics research data management. customer include majority top 20 pharmaceutical companies, major academic medical center U.S. Europe well biobanks, registry patient organization throughout world. Learn Organisation: Odysseus Data Services, Inc. Description: Odysseus established real-world evidence (RWE) solution provider enabling standardized systematic analytics observational data scale. Odysseus providing customer Software, Data Engineering Data Science solution supporting large-scale RWE generation. Odysseus active OHDSI contributor multiple key initiative working groups, including design development OHDSI platform ATLAS/WebAPI, ARACHNE ATHENA, OMOP CDM standards, curating maintaining OMOP standard vocabulary well development OHDSI analytical method (HADES) OHDSI distributed network research. Odysseus created ARACHNE platform goal linking multiple distributed life science healthcare organization single network enable standardized federated analytics observational data. Learn Data Partners CC ha set agreement growing list Data Partners create distributed network data sources. information Data Partners found page. Last Updated: 12 May 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutPrinciples & Policies Principles & Policies Table content Data Protection DARWIN EU Coordination Center (CC) executes study distributed data network using federated approach analytical code shared data partner aggregated study result shared CC. privacy-by-design approach additional measure added, example minimum cell count, comply local governance rules. data partner setup includes information procedure. information study execution found . latest version Record Processing Activities (ROPA) found below. information also see . Cookie Policy DARWIN EU Coordination Center website,we use cooky enablethe technical functioning thiswebsite.In addition, consent it, use cooky collect browsing experience website. enables u tocollect anonymous statistic help u improve website services. information see website. Conflict Interest study analysis conducted DARWIN EU shall conducted accordance principle scientific independence, set According ENCePP, scientific independence mean that: primary purpose study shall generate evidence potential scientific public health importance promote use medicinal product specific outcome; design research shall aim minimising potential bias; financial, commercial, institutional, personal interest particular outcome study (i.e., result interpretation) level organisation(s) initiating funding study coordinating study entity and/or researcher(s) conducting study, shall influence decision scientific aspect study direction, including data collection analysis, interpretation dissemination study results. relevant, definition principle set shall also applied. Related content Related document List item First published: 18/03/2023 EMA/51069/2023 List item First published: 18/03/2023 Last Updated: 27 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutEuropean Health Data Space European Health Data Space DARWIN EU connect European Commission's , initiative promote better exchange access different type health data. need use case medicine regulator decision-makers drive DARWIN EU's development, DARWIN EU also contributes developing EHDS joint action deliver European principle secondary use health data, known . Acting early flagship 'pathfinder' EHDS, DARWIN EU enable exchange healthcare data use healthcare delivery, policy-making research across Europe, fully complying data protection requirements. EHDS HealthData@EU Pilot Recently, EHDS2 Pilot Project wa initiated run till September 2024. project led French Health Data Hub (HDH)a French organisation aim ensure easy, unified, transparent secure access health data improve quality care support patients. Multiple consortium involved EHDS pilot, EU agency (EMA included), national platform international research infrastructures. consortium aim answer European Commissions call project concretely test EHDS practice creating network data platform European level, conducting cross-border research use cases, provide recommendation future EHDS. pilot project create first European network secondary use data projects, containing metadata search portal, data access request portal central services. Within network, project leader able querymetadata catalogue node ask data access several node single data application form. EMA authorised participant consortium partner within EHDS2 pilot project. EMAs use case thrombosis (see below) aim leverage DARWIN EU, among platforms. DARWIN EU EHDS2 pilot two complementary synergetic project secondary use health data. EMA Use Case EMAs use case aim investigate natural history coagulopathy use antithrombotic agent COVID-19 patient person vaccinated SARS-CoV-2. study ha previously conducted via EMA Framework Contract result study may used benchmarking (). important use case test wayDARWIN EU integrated EHDS future. Six specific objective study presented, increasing levelof complexity, chosen data partner considering capability data hold. important evaluate data different node combined, considering data available Common Data Model (CDM) via DARWIN EU data available node native format. wa also clarified CDM pre-requisite becoming node EHDS pilot. future, data sources, registriesfor example converted CDM. objective see different data source combined single study meaningful way. information: Last Updated: 27 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutWebinars DARWIN EU: multi-stakeholder information webinar Date: 24-02-2022 Location:Online, 10:30 - 12:00 Amsterdam time (CET) Event summary EMA organised multi-stakeholder information webinar to: introduce DARWIN EU recently appointed Coordination Centre; highlight opportunity collaboration answer stakeholder questions. Video recording Documents Last Updated: 10 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutCareers Careers Coordination Centre regularly ha open position example Programmers, Epidemiologists, Data Scientist join DARWIN EU team. posted page. Feel free contact Coordination Centre email like information: email address protected spambots. need JavaScript enabled view it. Last Updated: 18 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data DataData Network Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting benefit-risk decision making EU Regulatory Network. collaboration EMA Scientific Panel, Coordination Centre shall seek identify new data partner data source integrate new infrastructure technique network data partners. data partner enable DARWIN EU use data scientific studies, provide analysis result DARWIN EU Coordination Centre, accordance data protection rules. part data network directly Data Permit Authority, shown figure below. DARWIN EU expected bring board minimum ten data source every year. following requirement defined candidate data sources: Data source collecting health data routinely representative different type real-world data term data elements, setting (primary & secondary care), population origin (e.g. electronic health care records, claims) Data source collectively provide broad geographical coverage Data source containing patient-level data unique patient identifier linking record relating given patient Medicines prescribed dispensed identifiable quantity (e.g. doses, package size) date allowing calculate cumulative dos duration use linked individual unidentifiable patient Clinical event formally coded, accurate date linked individual unidentifiable patient Data already converted planned converted common data model access toreal-world healthcare data source ashospitals, primary care, health insurance, registriesandbiobanks. Data Sources selected consultation DARWIN EU Advisory Board andfollowing prioritisation criterion below: Continuous data collection (at least annual data updates) lag time le six month data availability analysis capture health outcome medicine prescribing dispensing Data converted Observational Medical Outcomes Partnership (OMOP) common data model current list Data Sources: N Data Partner Data Source Country 1 Centre hospitalier universitaire de Bordeaux France 2 University Oxford United Kingdom 3 University Tartu Estonia 4 Consorci Mar Parc de Salut Barcelona (PSMar), together Fundacio Institut Hospital del Mar dInvestigacions Mediques (IMIM) Spain 5 Mieur Implementation Exploitation B.V Netherlands 6 IQVIA Solutions BV Germany 7 IQVIA Solutions BV Belgium 8 Integraal Kankercentrum Nederland Netherlands 9 Fundacion Instituto Universitario para la Investigacion en Atencion Primaria de Salud Jordi Gol Gurina (IDIAPJGol) Spain 10 Finnish Institute Health Welfare (Finland) Finland 11 Clinical Academic Center Egas Moniz Health Alliance Portugal 12 Croatian Institute Public Health Croatia 13 University Oslo Norway 14 Semmelweis University Hungary 15 Health Data Hub France 16 University Oxford United Kingdom 17 Unidade Local de Sade de Matosinhos Portugal 18 FISABIO Spain 19 Agencia Espaola de Medicamentos Productos Sanitarios (AEMPS) Spain 20 Danish Health Data Registries Danish Health Data Registries (*Onboarding progress) Denmark Related document List item First published: 06/03/2024 Last Updated: 22 April 2024 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data DataWhy join network? join data network? role DARWIN EU Data Partner DPs part DARWIN EU network maintain relationship CC, realised two different ways: DPs active study participant co-author results. DPs onboarded eligible participate study undertaken DARWIN EU. mean that, feasibility assessment ha completed, may invited study and, agreeing participate, run centrally-developed code return aggregated result CC integration reporting. However, DPs data provider running common analytics returning results: expert database contribute aspect study including design, quality control, dissemination results. therefore believe suitably experienced DPs able opt-in multiple role study, including scientific epidemiological expertise report/publication development. also important necessary capacity building, DARWIN EU scale facilitate completion study parallel operational phase. expected participating DPs co-author publication resulting corresponding studies. DPs receive DARWIN EU training. provide periodic training workshops, part offered via remote learning environments, DPs aware latest best practice data use management, study development method tools. Onboarded DPs expected actively participate thriving DARWIN EU community, allow exchange experience opportunity continuing improvement growth. benefit DARWIN EU DPs? Working benefit EMA EMRN generation real-world evidence critical medicine regulation European level, example diseases, patient populations, use, safety effectiveness medicines, including vaccines, throughout lifecycle medicinal product. Supporting decision-making use, safety effectiveness medicines, wide range stakeholder benefit, patient healthcare professional health technology assessment body pharmaceutical industry. Participation high-impact publication derived study undertaken DARWIN EU. Assurance scientific independence, freedom decline studies, respect institution approval procedures. Facilitated scientific collaboration, connection peer learning becoming part thriving academic/medical/regulatory network community. Increased external visibility DPs data, expanding opportunity participate studies, joint research project grant proposal beyond DARWIN EU, helping long-term sustainability DP. Boosted opportunity participate international study larger regulatory impact, provide invaluable resource prepare respond future healthcare crisis pandemics. Improved interoperability understanding data, enhancing data partner internal decision-making processes, potential propagate learning inside institution enhance procedure generally improve underlying healthcare systems. Added possibility auditing/refining/visualising data open source tooling understanding data set better, including integrative analyses, revealing potential flaw continued improvement. Increased transparency analysis reproducibility, enabling study easily transposed data source multiplied impact (e.g., publications). Increased speed performing studies, improved performance, accelerated research (months/years weeks): allowing DPs undertake study le time, le resources. Access training platform data standardisation, quality control, analytics Coordination Centre. Exposure collaborative experience world-class expert real-world evidence generation using OMOP CDM. Last Updated: 27 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data DataHow join network? join data network? Open Call DPs described document welcome expression interest data custodian Europe wishing considered candidate DP DARWIN EU. include primary secondary care data sources, claim databases, biobanks, etc. open data source, Open Call instrument facilitate level playing field interested institution participate DARWIN EU aim compile relevant information candidate Data Partners support decision making EMA determine DPs formally invited join initiative. express interest? process simple. DPs interested need provide information data source(s) Expression Interest (EoI) form. moment, form Excel spreadsheet, accessible here: Potential DPs download form complete offline. form duly completed, must sent authorised representative (i.e. person institution authority submit applications) following email address: email address protected spambots. need JavaScript enabled view it. happens submission Expression Interest? Upon receipt, CC acknowledge receipt email reply sender. Expression Interest correctly received checked CC completeness, consistency scope. Expressions Interest deemed incomplete, inconsistent, scope rejected stage, candidate informed correspondingly within two week receipt date. Rejected submission due lack completeness consistency re-submitted correcting EoI. EoIs become part list interested potential DPs. list reviewed CC EMA least twice year, corresponding EoIs received following date every year: 30th April 31st October Although deemed ordinary cut-off dates, CC EMA reserve right reviewing application point time, depending need network forthcoming studies.Following request EMA, CC may announce termination Open Call DPs. review process examine Expressions Interest consider factor type data, size, geographical representativeness, added value network, perceived data quality, governance procedures, coverage specific populations, past experience studies, potential intention convert data status mapping OMOP CDM, etc., result short list DPs approached. Final decision short list rest EMA considering current future need studies. Shortlisted DPs may approached CC discus outstanding question CC/EMA experts, directly invited initiate formal onboarding process, consist several step finish signature agreement CC (see ), signal official participation DARWIN EU Data Partner. important note guarantee given candidate DP regard selection effective incorporation DARWIN EU onboarding process successfully completed agreement CC ha signed. Conversely, submission EoI non-binding candidate DPs, may withdraw selection process longer interested. received EoIs remain list interested potential DPs (unless applicant express wish removed email address mentioned above) shortlisted review round. Additionally, Expression Interest form allows DPs explicitly agree information submit automatically included public EMA Metadata Catalogue data sources, increasing discoverability researcher conduct scientific studies. FAQ Open Calls No. considered candidate DP, first step submit Expression Interest. Yes, unless duly justified, case appropriate justification included. information contained EoI primarily used purpose evaluating candidacy formally become DARWIN EU Data Partner. access associated Data Protection Notice . Additionally, providing consent response specific question EoI form, potential DP agree EoI information used populate EU Metadata Catalogue, EMA initiative help improve data discoverability transparency. Catalogue intended public use, read associated Data Protection Notice No, continuously open call, please bear mind cut-off date (30th April, 31st October) review selection. No. CC may contact clarify certain aspect datasets EoI, invite initiate formal onboarding process. latter successfully completed agreement signed, DARWIN EU DP. onboarding process consists several quality technical check ensure readiness DARWIN EU studies, plus explanation term condition participation agreement legal provision apply relationship CC. duration vary 1 2 months, ordinarily. No. onboarding process ha successfully completed agreement CC ha signed. Related document List item First published: 18/12/2023 List item First published: 26/03/2023 Last Updated: 18 December 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Methods Methods DARWIN EU implement necessary paradigm shift delivery reliable evidence regulatory decision-making utilisation, safety effectiveness medicinal product throughout lifecycle. DARWIN EU significantly scale number study number databases, also substantially bringing cost study. make DARWIN EU ground-breaking venture Real-World Evidence generation. ambitious endeavour cannot result simply scaling traditional approach used today. implement DARWIN EU, must remove obstacle currently prevent exploitation existing data required speed quality. need setup procedure tool federated study execution compliant governance rule privacy regulations. requires improve interoperability data, develop standardised analytics, develop tool host artefact created study re-used future studies. information topic see menu item left. Last Updated: 12 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Study Execution Study Execution DARWIN EU Studies executed using so-called federation approach shown figure below. approach Data Partners distributed data network keep full control data. patient level data shared Coordination Centre (CC) aggregated study results. Study Execution process divided following Phases: Exploration, Initiation, Implementation, Execution, Dissemination: Exploration Phase EMA interacting Coordination Centre explore feasibility study request respect preferred design, available data, resources, timelines. 1. Study Request Research question originate EU Regulatory Network need information support authorisation monitoring medicinal product subsequent decision-making. may include, example, query incidence prevalence disease European population, drug utilisation pattern specific product, collection additional data potential safety signal, evaluation association drug clinical outcome assessment effectiveness risk minimisation measure. envisaged future, research question may also originate stakeholder European Commission, European Centre Disease Prevention Control (ECDC), Health Technology Assessment (HTA) body payers. requester, together EMA, prepares Feasibility Assessment Form containing: short title request, regulatory background motivating query, important information understanding query, product and/or event(s)/outcome(s) interest, objective, proposal study design relevant design consideration choice data source methodological aspects. choice study design supported providing, range possible analysis different level complexity (Routine repeated, Off-the-shelf, Complex), implication term database needed timelines. 2. Feasibility Assessment Coordination Centre performs feasibility assessment EMA review. aim ass feasibility study based relevant factor concerned study, including, example, number exposed patients, number events, time period, minimum duration exposure considered, time lag occurrence event, feasibility implementing study design available database criterion depending study. feasibility assessment principle use information already available CC characteristic database via pre-calculated Data Dashboards relevant information. necessary, simple data analysis could performed relevant database available, example simple count number patient exposed medicinal product experienced clinical event defined time period. data analysis may performed limited number database Coordination Centre undergo quality assurance process performed full study. result feasibility analysis next included Feasibility Assessment Form recommendation regarding conduct study. decision initiate study formally made EMA. Initiation Phase contractual agreement setup selected Data Partners, Study Team formed, Conflicts Interest procedure applied. Contractual Agreements Upon green light conduct study, Coordination Centre responsible contractual agreement onboarding Data Partners study. standardised work order initiated DARWIN EU CC indicates agreed timeline budget study. data partner sign standard work order agreement specifies activities, budget, timelines. Team Formation level involvement study team strongly depend Study Type, i.e., simple shelf study may run near automatically fast review step small team. complex study larger team may proposed Study Operations. team consist data scientists, epidemiologists, clinical domain expert responsible Evidence Generation Evidence Synthesis. team completed Data Stewards participating Data Partners work secured collaboration space. Documentation assessment Conflicts Interest Potential investigator assigned DARWIN EU study shall requested declare existing direct indirect interest pharmaceutical company. term defined . detail DARWIN EU Conflict Interest Procedure found section. EMA review submitted form approve team composition. Implementation Phase study artefact created Study Outline, Study Protocol, Cohort Definitions, Study Package. Study Outline agreement reached EMA DARWIN EU CC conduct DARWIN EU study, Study Outline Form completed describing aspect as: Study Team, Data Sources, Choice study type related study design including methodological aspects, governance board approval timelines. completed Study Outline Form next submitted EMA approval. Study Outline Form approved EMA, protocol DARWIN EU study generated. Study Outline approved signed-off EMA archived DARWIN EU CC study specific project file. Study Protocol Development agreement reached EMA DARWIN EU CC Study Outline, Study Protocol generated following . Upon completion Draft Study Protocol, Study Protocol need approved EMA. Study Protocol approved signed-off EMA, study protocol archived DARWIN EU CC study specific project file. Next, final study protocol uploaded Kick-off meeting Following finalisation protocol prior study execution, kick-off meeting organised Study Project Manager/Principal Investigator study team member explain protocol, agree roles, responsibility timeline study execution. Governance Board Approval Protocol approval study site often required comply local implementation relevant law directive various European states. data custodian responsible protocol approval local governance board prior study execution specified Framework Contract Data Partner. Cohort Construction Assessment needed, phenotype target outcome cohort work across included data source generated. facilitated , addition . latter provides in-depth characterisation phenotype definitions, secular trend time, standard well orphan source code (not included source code may interest), cohort participant/s characterisation. Study Package Creation analysis pipeline study type described within used need instantiated cohort interest right parameter setting obtain Study Package. example, study estimate incidence prevalence health outcome Package used parameter set according protocol. study initiation, test run analytics performed subset data source simulated set patient quality control check performed. test passed, final package released private repository version- controlled . package distributed data partner local execution agains OMOP CDM. Execution Phase Data Partners execute Study Package OMOP CDM review aggregated results. includes applying quality check study result data privacy check assure aggregated data shared compliant local governance procedures. Execution Iterations data partner locally execute analytics OMOP-CDM review approve aggregated result returning Coordination Centre. Sometimes multiple execution iteration performed, additional fine tuning code base needed. service desk available study execution support. Quality Control study result data source checked made available team Digital Research Environment Dissemination Phase start. result locked timestamped reproducibility transparency. Dissemination Phase evidence synthesised report result dashboards, potentially publications. study artefact retained Evidence Synthesis result data source combined produce table figure needed report Digital Research Environment. amount effort Evidence Synthesis strongly depend study complexity, i.e., le effort off-the-shelf routine repeated study effort complex studies. pooling database-specific result pre-specified per protocol, including rules/diagnostics precluding inclusion database use meta-analytic approach combine data-specific estimates. result reviewed, conclusion formed context prior knowledge relevant. Dashboard Instantiation study executed OMOP-CDM, large amount study result generated many data sources. Therefore, dashboard form web application made simplify exploration results. uploaded study result easily combined single folder dashboard instantiated. web application either made publicly available necessary, made available behind security layer. Reporting Study Results study team writes report and/or publication. study report written accordance Guideline good pharmacovigilance (GVP) module VIII, (EMA/813938/2011) guidance ENCePP. (final) study report(s) uploaded . Study finding preferably considered publication open access. publication guided Uniform Requirements Manuscripts Submitted Biomedical Journals: Writing Editing Biomedical Publication International Committee Medical Journal Editors (). Retention closure study generated documents, used analytics, study result archived enable reproducibility. Last Updated: 16 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Data Interoperability Data Interoperability Increasing productivity reliable Real World Evidence generation requires standardisation automation analytical processes. cannot done without standard representation data. Full interoperability data needed respect structure (syntactic interoperability) coding system (semantic interoperability) using Common Data Model (CDM). OMOP Common Data Model DARWIN EU using (OMOP CDM), ismaintained (OHDSI) global community. OHDSI community also ha active led Erasmus MC. OMOP CDM provides syntactic semantic interoperability. Syntacticly, OMOP CDM relational database consisting table demographic clinical event ('Standardised Clinical Data', information care setting ('Standardised Health System'), health economics ('Standardised health economics'), record derived clinical table ('Standardized derived elements') 'Standardized metadata'). semantic layer provided 'Standardized vocabularies', ha populated OMOP standard concept relationships. standardized vocabulary centrally maintained distributed. semantic interoperability especially important Europe myriad terminology system languages. Tools available data standardisation, data quality, data analysis, commercially public domain (see example, ). OMOP CDM designed federated querying analytics, whereby application run locally data partner site aggregated result shared. privacy-by-design approach compliant data protection requirements. OMOP CDM proven model large-scale observational health studies. ha used including study informed regulatory decision-making, large number European database already available OMOP CDM format. example, (EHDEN) project investing 17M private/public funding standardising health data OMOP-CDM Innovative Medicines Initiative (). adoption OMOP CDM growing Europe, formed. Quality Control Mechanisms part Data Partner (DP) onboarding, DARWIN EU Coordination Centre (CC) ass quality data. DARWIN EU data quality package aligned EMA. benefit interoperable data model, dat use standardised tooling extract objective data quality metrics. purpose currently using two packages: R Package support onboarding process Data Partner (DP) DARWIN EU Data Network. extract statistic DP's OMOP CDM instance produce Word document. goal onboarding report provide insight completeness, transparency quality performed Extraction Transform, Load (ETL) process readiness data partner onboarded DARWIN EU data network participate DARWIN EU studies. onboarding report consists three sections. Clinical Data section report data table counts, data density, follow-up period length date ranges. Vocabulary Mapping section especially important data quality, show concept mapping coverage per domain top mapped/unmapped codes. Finally, Technical Infrastructure section give insight readiness DP execute studies, overview query timings, installed package system information. CdmOnboarding run on-site DP, extract data directly OMOP CDM pre-calculated table (OHDSI R package OMOP CDM characterisation). resulting Word document required annex main Onboarding Document, delivered upon first onboarding. However, CdmOnboarding required run every CDM refresh, result shared CC inspection. R package maintained OHDSI community. performs set 3000 standardised check populated OMOP CDM instance. goal evaluate observational data quality systematic transparent way. quality check organized according us system category context represent strategy assessing data quality. DQD contains 24 check defined within framework systematically executed relevant table field OMOP CDM. Examples check executed DQD are: doe table/field exist, populated doe right data type (cdmField, cdmDataType, isRequired) doe field follow standard semantic interoperability (isStandardValidConcept) gender-specific diagnosis/procedure associated correct person gender (gender) measurement value within extreme range (valueLow, valueHigh) Clair Blacketer, Frank J Defalco, Patrick B Ryan, Peter R Rijnbeek, Increasing trust real-world evidence evaluation observational data quality, Journal American Medical Informatics Association, Volume 28, Issue 10, October 2021, Pages 22512257, External link Last Updated: 26 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Standardised Analytics Standardised Analytics DARWIN EU Coordination Centre (CC) ha set maximise value efficiency real-world evidence regulator stakeholder Europe. mind, recognised Standardised Analytics needed speed evidence generation whilst preserving quality, reproducibility, transparency proposed research. Standardised Analytics enabled use OMOP Common Data Model (OMOP CDM). ha several advantages: risk different implementation study design would case common protocol shared translated code programmer site. Differences study outcome therefore related data instead study implementation. Standardised Analytics made Study Type re-used specific study defining study parameters. example, Drug Utilisation Analytical tool made parameter Population Drugs Interest. Standardised Analytics produce standardised help EMA committee streamline assessment results. Standardised Analytics tested validated following agreed Quality Assurance Processes test data set OMOP CDM format. CC developing Catalogue Standard Data Analyses accommodate requested study designs. study DARWIN EU deliver grouped anticipated level complexity: Off-the-shelf, Complex, Complex. Off-The-Shelf Complex Studies repeated periodically pre-specified regularity (e.g. yearly), called Routine Repeated Analyses. development Common Analytics driven initial list study Establishment Phase DARWIN EU. find current version catalogue. discussion stakeholder 2023 catalogue maintained regularly. Catalogue Standard Data Analyses Catalogue Standard Data Analyses list various analysis currently supported CC. Off-the-shelf study mainly characterisation question executed generic protocol. includes disease epidemiology, example estimation prevalence, incidence health outcome defined time period population groups, drug utilization study population patient level. Study Type/s Patient-level characterisation classified shelf Study Design Cohort analysis. Participant/s Patient-level characterisation study include one cohort/s people newly diagnosed 1 pre-specified condition/s amount data visibility diagnosis, record condition/s previous year (or previous history). Additional eligibility criterion could apply follows, incorporated sensitivity analyses: Additional restriction/s could apply based socio-demographics, e.g., people aged 18 older time diagnosis Additionally, people competing (differential) diagnosis could also excluded (e.g., people rheumatoid arthritis history psoriatic arthritis could excluded minimise misclassification) Follow-up Participants followed date new diagnosis (index date) earliest following: loss follow-up, end data availability, pre-specified time period (e.g. 1 year index date) death. Analyses Details discussed programming pipelines, likely patient-level characterisation include: Automated large-scale characterisation, including recorded baseline characteristic available data index date, based code/s, classified condition (medical history), medicine/s use, procedure/s Pre-specified patient-level characteristic and/or index date, based pre-existing code list definition (e.g., history type 2 diabetes, Charlson comorbidity index) Pre-specified patient-level characteristic and/or index date, based concept descendant previously validated algorithm available Incidence rate/s pre-specified outcome/s within pre-specified time period (e.g. 1 year) Prognosis / progression pre-specified outcome within pre-specified time, e.g., cumulative incidence certain event mortality within 1- 5-years diagnosis Standard care description, including n (%) receiving pre-specified list medicine/s, device/s procedure/s, combination within pre-specified time window diagnosis Study Type/s Patient-level DUS analysis classified shelf studies. Patient-level DUS offer possibility include population-level DUS analysis part analysis. Study Design New drug/s user cohort Participants Patient-level DUS analysis include one cohort/s incident drug user least 1 year data visibility, use drug/drug class previous year. Additional eligibility criterion could apply follows: Source population could restricted specific subpopulation certain socio-demographic clinical feature/s, e.g., people diagnosis rheumatoid arthritis start take disease-modifying anti-rheumatic drug (DMARD) Additional restriction/s could apply per product label, indication, study aim/s, e.g., people aged 18 older time therapy initiation Follow-up Participants followed date therapy initiation (index date) earliest loss follow-up, end data availability, death. Patients might censored time discontinue treatment switch alternative therapy. Outcome/s following outcome/s obtained, potentially stratified pre-specified criterion (age bands, sex, calendar year month), pre-specified criteria: New drug user cohort/s patient-level characteristic index date Indication (where available) Initial dose/strength (as prescribed/dispensed therapy initiation, available) Cumulative use within pre-specified time period (e.g. 1 year) based number prescription dose/strength Treatment duration Count repeated prescription pre-specified time period (e.g. 1 year) Analyses Patient-level DUS analytics include: Large-scale characterisation patient-level feature based code/concept descendants, including socio-demographics, comorbidity, previous medicine/s use time history, year, and/or month previous index date Frequency % indication/s, based pre-specified list diagnosis recorded therapy initiation (where available) Reporting minimum, p25, median, p75, maximum initially prescribed dispensed dose/strength (where available) Reporting minimum, p25, median, p75, maximum cumulative use within pre-specified time period (e.g. 1 year) Reporting minimum, p25, median, p75, maximum treatment duration Reporting minimum, p25, median, p75, maximum number repeated prescription index drug pre-specified time period (e.g. 1 year) Study Type Population-level DUS analysis classified shelf studies. Study Design Population-level cohort. Participants Population-level analysis include entire source population least time (typically 1 year) data visibility available start study period. Additional eligibility criterion apply follows: Analyses incidence drug use exclude prevalent user drug/drug class index date and/or previous (washout) year study population could restricted specific subpopulation certain socio-demographic e.g., age 18 older, history pre-specified clinical feature/s, e.g., people prior diagnosis rheumatoid arthritis cases, minimum follow-up requested e.g., treatment pattern analysis Outcome/s following outcome/s obtained, potentially stratified pre-specified criterion (age bands, sex, calendar year month): Population-based incidence rate use drug/drug class calendar time. Periods could calendar days, weeks, months, quarter years. Population-based prevalence use drug/drug class given time point (point prevalence) within given time period (period prevalence). Periods could calendar days, weeks, months, quarter years. Follow-up Follow-up start pre-specified calendar time point pre-defined index date , e.g., 1st January 1st month, continue pre-specified time period, typically week, month, quarter year. Analyses Population-level DUS analysis use analytical pipeline Population-level descriptive epidemiology study (see separate subsection). Incidence rate number new user (with pre-specified washout) numerator, total population person-years (except prevalent users) denominator. Prevalence calculated number user (prevalent new) whole source population specific time point (i.e., point prevalence) specific time window (i.e., period prevalence). may stratified socio-demographics (e.g., age band sex) and/or calendar period. Additional criterion (e.g. disease severity/duration) may need considered integrated pre-specified future studies. Study Type/s Population-level descriptive epidemiology classified shelf studies. Study Design Population-level cohort Participant/s Population-level analysis include entire source population least time (typically 1 year) data visibility available index date. Additional eligibility criterion apply follows: Analyses disease incidence exclude patient previous/prevalent history disease index date and/or previous (washout) year and/or previous history source population could restricted specific subpopulation certain socio-demographic clinical feature/s, e.g., people aged 50+ index date Outcome/s following outcome/s obtained, potentially stratified pre-specified criterion (age bands, sex, calendar year month), pre-specified criteria: Population-based incidence disease/condition (or group diseases/conditions) given time point time (stratified calendar period) Population-based prevalence disease (or group diseases/conditions) given time point (e.g., pre-specified date), and/or time (e.g., stratified month year) Follow-up Follow-up start pre-specified calendar time point pre-defined index date , e.g., 1st January 1st given month, continue pre-specified time period, typically week, month year Analyses Incidence rate number newly diagnosed people numerator, total population (satisfying study eligibility criteria) denominator. Prevalence calculated number people diagnosis (prevalent new) whole source population specific date (point prevalence) window time (period prevalence). stratified socio-demographics (e.g., age band sex) and/or calendar period. criterion (e.g. disease severity/duration) may need considered integrated future studies. Complex study requiring development customisation specific study designs, protocols, analytics, phenotypes. includes study safety effectiveness medicine vaccines. Motivation Although new user cohort preferred, prevalent user design desirable instances, particularly recently marketed medicine compared existing heavily used active comparator, many new user recently launched previous user existing active comparator medicine. lead situation new user new medicine use active comparator scarce, potentially non representative desired target population user new drug. Prevalent user cohort study used recent year study potential effect medicine like ACE inhibitor alpha-1-blockers SARS-CoV-2 infection and/or COVID-19 severity [; ]. Study Type/s Prevalent user active comparator cohort study classified complex analyses. Study Design Prevalent user cohorts. Participant/s least two cohorts, including cohort prevalent user least one drug/medicinal product investigation (target cohort) cohort prevalent user least one drug/medicinal product active comparator (comparator cohort). Typically, prevalent user cohort defined previous use target/comparator medicine specific time period pre-specified duration. Follow-up Participants cohort followed specific index date different date treatment initiation. Based previous examples, typically calendar date, e.g. 1st March 2022. Two possibility analysis offered: fixed follow-up analysis, follow-up continue death, loss follow-up pre-specified time period (e.g., 3 years) regardless treatment duration treatment analysis, follow-up continue treatment cessation, death, loss follow-up Outcome/s One study outcome pre-specified, based previous DARWIN EU algorithm newly developed validated ones. addition, long list negative control outcome assessed, known causal association drug/s medicinal product/s study. Analyses Details discussed programming pipelines, new user cohort analysis include: Large-scale characterisation participant target comparator cohorts, including feature available data index date. Large-scale propensity score (LSPS) estimated probability exposure (target cohort) conditional available covariates available data prevalence >1%. LSPS estimated using Lasso regression. Different new user cohorts, LSPS estimated using information available index date, case prevalent user date therapy initiation different previously specified date. Incidence rate/s outcome interest target comparator cohort LSPS matching, stratification, inverse probability weighting Diagnostic/s: Covariate balance: plot produced depicting standardized mean difference/s target comparator cohort available covariates (x axis) propensity score matching/stratification/weighting (y axis) [see Figure 4 illustrative example] Equipoise: plot distribution propensity score stratified target v comparator cohort [see Figure 4 illustrative example] Analyses conducted insufficient data, based pre-specified minimum detectable rate ratio (e.g., MDRR>5) Optional: addition two above, residual confounding/systematic error available estimation, based number negative control outcome/s significantly associated exposure interest Rate Ratios Hazard Ratio/s 95% confidence interval estimated using Poisson Cox model respectively, comparing target v comparator (reference) cohort LSPS matching, stratification, inverse probability weighting Optionally, calibrated RR HR estimated empirical calibration using negative control outcome Study Type/s New user active comparator cohort study classified complex analyses. Study Design New user cohorts. Participant/s least two cohorts, including cohort new user least one drug/medicinal product investigation (target cohort) cohort new user least one drug/medicinal product active comparator (comparator cohort). Typically, new user cohort exclude previous user either cohort previous year well people <1 year data visibility inclusion. Follow-up Participants cohort followed therapy initiation date (index date). Two possibility analysis offered: fixed follow-up analysis, follow-up continue death, loss follow-up pre-specified time period (e.g., 3 years) regardless treatment duration treatment analysis, follow-up continue treatment cessation, death, loss follow-up Outcome/s One study outcome pre-specified, based previous DARWIN EU algorithm newly developed validated ones. addition, long list negative control outcome assessed, known causal association drug/s medicinal product/s study. Analyses Details discussed programming pipelines, new user cohort analysis include: Large-scale characterisation participant target comparator cohorts, including feature available data index date Large-scale propensity score (LSPS) estimated probability exposure (target cohort) conditional available covariates available data prevalence >1%. LSPS estimated using Lasso regression Incidence rate/s outcome interest target comparator cohort LSPS matching, stratification, inverse probability weighting Diagnostic/s: Covariate balance Equipoise: plot distribution propensity score stratified target v comparator cohort Analyses conducted insufficient data, based pre-specified minimum detectable rate ratio (e.g., MDRR>5) Optional: addition two above, residual confounding/systematic error available estimation, based number negative control outcome significantly associated exposure interest Rate Ratios Hazard Ratio/s 95% confidence interval estimated using Poisson Cox model respectively, comparing target v comparator (reference) cohort LSPS matching, stratification, inverse probability weighting Optionally, calibrated RR HR estimated empirical calibration using negative control outcome Study Type/s Self-controlled case risk interval study classified complex analyses. Study Design Self-controlled case risk interval (SCRI). Participant/s like SCCS, SCRI study include one cohort/s people suffer specified safety event/group event/s least record/s. Additional eligibility criterion could apply based socio-demographics clinical characteristics. Follow-up SCRI design us pre-specified control interval relative exposure (typically vaccination) date control time. control interval exposure, must defined priori. therefore pre-define study-specific follow-up pre- and/or post-exposure control interval periods, participant followed/observed pre-specified control interval, immediately after/during exposure medicinal product. Similar SCCS, specified control interval (either pre- and/or post-exposure) period considered baseline unexposed, whilst treatment episode/s exposed. Outcome/s One study outcome pre-specified, based previous DARWIN EU algorithm newly developed validated ones. Ideally, outcome acute presentation clear accurate diagnosis date. addition, long list negative control outcome assessed, known causal association drug/s medicinal product/s study. Analyses Details discussed programming pipelines, SCRI include: Large-scale characterisation SCRI participant time diagnosis, including recorded feature available data index date, based SNOMED code/s Pre-specified patient-level characteristic and/or diagnosis, based pre-existing cohort definition (e.g., history type 2 diabetes, Charlson comorbidity index). Pre-specified patient-level characteristic and/or diagnosis, based concept descendant previously validated algorithm available Incidence rate/s pre-specified control interval exposed time Diagnostic/s: Event-exposure independence: histogram time event date end observation individual censored uncensored plotted ass potentially event-dependent observation time Analyses conducted insufficient data, based pre-specified minimum detectable rate ratio (e.g., MDRR>5) Optional: addition two above, residual confounding/systematic error available estimation, based number negative control outcome significantly associated exposure interest Incidence rate ratio 95% confidence interval estimated using conditional Poisson regression models, comparing exposed v control interval period. Adjusted incidence rate ratio 95% confidence interval calculated adjustment age seasonality Optionally, calibrated incidence rate ratio estimated empirical calibration adjusted incidence rate ratio based observed systematic error Study Type/s Self-controlled case series classified complex (C3) analyses. Study Design Self-controlled case series (SCCS). Participant/s SCCS include one cohort/s people suffer specified safety event/group event least record/s, hence denomination case series. Additional eligibility criterion could apply based socio-demographics clinical characteristics. Follow-up pre-define follow-up period according exposure history. Typically, participant SCCS followed time (pre-exposure), (exposed) post-exposure medicinal product. Sometimes, washout imposed beginning exposure period. Pre- post-exposure period considered baseline unexposed, whilst treatment episode/s exposed. washout period disregarded accounted analyses. See Figure 3 illustration. analyses, first event considered participant minimise biases, follow-up censored first event. Outcome/s One study outcome pre-specified, based previous DARWIN EU algorithm newly developed validated ones. Ideally, outcome acute presentation clear accurate diagnosis date. addition, long list negative control outcome assessed, known causal association drug/s medicinal product/s study. Analyses Details discussed programming pipelines, SCCS include: Large-scale characterisation SCCS participant time diagnosis (index date), including recorded feature available data date, based SNOMED code/s Pre-specified patient-level characteristic index date, based pre-existing cohort definition (e.g., history type 2 diabetes, Charlson comorbidity index). Pre-specified patient-level characteristic index date, based concept descendant previously validated algorithm available Incidence rate exposed unexposed time Diagnostic/s: Event-exposure independence: histogram time event date end observation individual censored uncensored plotted ass potential event-dependent observation time Analyses conducted insufficient data, based pre-specified minimum detectable rate ratio (e.g., MDRR>5) Optional: addition two above, residual confounding/systematic error available estimation, based distribution result negative control outcome analysis Incidence rate ratio 95% confidence interval estimated using conditional Poisson regression models, comparing exposed v baseline period. Adjusted incidence rate ratio 95% confidence interval calculated adjustment age seasonality Optionally, calibrated incidence rate ratio estimated empirical calibration adjusted incidence rate ratio based observed systematic error Study Type considered complex epidemiological study require bespoke modelling intervention like public health restriction calculation population- and/or patient-level disease epidemiology estimates. analysis take form interrupted time series analyse impact intervention (e.g., public health restriction change/s law) occurrence outcome population-level (e.g., incidence COVID-19 v imposition public health restrictions) and/or patient level (e.g., characteristic people newly diagnosed v change/s law). Study Design Population-level cohort/s Patient-level characterisation. Participant/s Population-level analysis include entire source population least 1 year data visibility available start study period. Additional eligibility criterion could apply population-level disease epidemiology (see above). Stratification used case Difference-in-difference study obtain control (unimpacted) counterfactual comparison. Patient-level analysis restricted newly diagnosed subjects, using 1-year washout, potential additional eligibility (see above). Exposure/s least one public health measure, regulatory action (e.g., banning change use medicinal product) intervention imposed known date time. case Difference-in-difference analyses, affect known subpopulation, another subpopulation affected intervention acting unimpacted counterfactual. study period pre-specified, divided pre-exposure (i.e., unimpacted time) post-exposure (i.e., impacted) calendar time. Difference-in-difference studies, observed pre- v post-exposure change Exposed compared Unexposed subpopulation. lag period intervention start post-exposure study period could considered allow action impact study outcome/s. Outcome/s following estimated pre-specified study period, including least 1 year intervention/s interest: Population-based incidence rate condition/group condition/s time Population-based prevalence condition/group condition time Difference-in-differences: population-based incidence prevalence condition/group condition/s time, exposed v unexposed population separately patient level, two cohort newly diagnosed people studied, namely diagnosed period (unimpacted) v intervention (impacted). following outcome/s obtained compared cohorts: Patient-level characteristic amongst newly diagnosed v intervention (Optional) Patient-level characteristic amongst prevalent case given date/s v intervention Prognosis / progression pre-specified outcome within pre-specified time diagnosed v exposure interest Standard care description, including n (%) receiving pre-specified list medicine/s, common combination among diagnosed v exposure interest (Optional) Standard care description, including n (%) receiving pre-specified list medicine/s, common combination among prevalent case specified date v exposure interest Follow-up population-level analyses, follow-up start pre-specified calendar time point, least 1 year proposed intervention, continue least 1 year it. patient-level analyses, follow-up go date diagnosis (newly diagnosed cases) prespecified date (prevalent cases) earliest loss follow-up, end data availability, death. Analyses Incidence prevalence rate/s disease time estimated detailed section 3.1. available, segmented regression method used estimate impact proposed intervention/s pre- v post-intervention change/s trend population-level prevalence and/or incidence. Coefficients segmented regression reported quantify impact intervention/s incidence prevalence use, together Durbin-Watson residual diagnostic. case autocorrelation, ARIMA/X model fitted instead segmented regression data permits. difference-in-difference studies, parallel trend intervention identified requisite type study. confirmed, Difference-in-difference model used subtract difference unexposed group exposed one whilst controlling time varying factors, thus estimating causal effect intervention. patient-level analyses, standardised mean difference covariates comparison new case diagnosed prevalent case pre- v post-intervention period obtained measure impact exposure profile new cases. Study Type Trend analysis RMM effectiveness considered complex DUS require bespoke modelling intervention like risk minimization measure (RMM) completion population- and/or patient-level DUS. typically take form interrupted time series analyse impact regulatory action use medicine population-level (e.g., incidence use v RMM) and/or patient level (e.g., characteristic new drug user v RMM). Study Design Population-level cohort New drug user cohort Participant/s Population-level analysis include entire source population least time (typically 1 year) data visibility available start study period. Additional eligibility criterion could apply population-level DUS (see above). Patient-level analysis restricted new prevalent user specified list medicine/s medicinal product/s specified time point/period, using washout, potential additional eligibility criterion considered (see above). Exposure/s least one RMM imposed known date time. RMM (or series RMMs) main study exposure/intervention analysis. study period therefore pre-specified, divided (i.e., unimpacted time) (i.e., impacted) calendar time. lag period publication communication RMM start post-exposure study period could considered allow RMM impact study outcome/s. Outcome/s following estimated pre-specified study period, including least 1 year RMM exposure/s interest: Population-based incidence rate use drug/drug class time Population-based prevalence use drug/drug class time patient level, two cohort new prevalent drug user/s studied, namely initiated user treatment interest period (unimpacted) v RMM (impacted). following outcome/s obtained compared cohorts: New drug user cohort/s patient-level characteristic index date (Optionally) prevalent drug user cohort/s patient-level characteristic index date Follow-up population-level analyses, follow-up start pre-specified calendar time point, least 1 year imposed RMM, continue least 1 year it. patient-level analyses, follow-up go date therapy initiation (for new users) pre-specified date (for prevalent users) earliest loss follow-up, end data availability, death. Patients might censored time discontinue treatment switch alternative therapy, date RMM. Analyses Incidence prevalence rate/s drug/s use time estimated detailed section 2.1. available, segmented regression method used estimate impact imposed RMM/s population-based pre- v post-intervention trend drug/s use. Coefficients segmented regression indicating difference trend period immediately intervention (step change) reported quantify formal test impact RMM/s incidence prevalence use, together Durbin-Watson residual diagnostic. case autocorrelation, ARIMA/X model fitted instead segmented regression, data permits. patient-level analyses, standardised mean difference covariates comparison new/prevalent drug user pre-RMM v post-RMM period obtained measure impact RMM profile new drug users. Additionally, measure patient-level DUS provided, stratified time therapy initiation pre post RMM. Complex Studies Studies cannot rely electronic health care databases, would require complex and/or novel methodological work. complex study design defined moment Quality Assurance Software Development Software Quality Assurance, also called Software Testing Life Cycle process, aim assure software doe supposed according Software Requirements Specification (SRS). code quality assurance process within DARWIN EU follow agile development method shown Figure 1. Figure 1. Agile software development method method continuously applied software lifecycle monitor improve quality. process monitored Quality Assessment Lead interacts closely Product Owner. contains following steps: Plan: Plan Phase agreed code require testing part prioritized next sprint. Design: design phase Software Specification Requirements (SRS) Test Plan created updated (in following sprints). SRS provides benchmark test planning since specifies function non-functional requirements, situation expected applied in, whom. Test Plan living document get updated development sprints. Develop: develop step quality measure implemented code base get updated according Test Plan. includes creation unit test etc. Test: quality control phase process software tested according plan ensure provides correct results, ha cross platform compatibility, stable, efficient. outcome test recorded taken account next sprint. Issues identified flagged bug either immediately rectified case significant error (e.g. incorrect application functionality providing false answers), (deemed enhancements) fixed next development cycle package, e.g., software requires much memory. Deploy: phase major minor software release created code kept development status improvement. Quality software development focus 2 main themes: 1. doe software produce correct results. tested using small scale example (units tests) correct answer known. 2. software run required platform without producing errors. examined checking, e.g., incorrect parameters, platform difference (both database management operating systems). Last Updated: 26 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Research Memory Research Memory DARWIN EU Coordination Centre (CC) developing library store re-usable study artefact concept set phenotype definitions. need make artefact Findable Accessible Interoperable Re-usable (FAIR). moment CC working library OMOP-based phenotype reused (with without modifications) conduct study DARWIN EU network: DARWIN EU Cohort Knowledge base (DECK) Solid well defined algorithm necessary identify people set characteristic (e.g. coded diagnosis recorded prescription/s dispensation/s specific medicine) logic (e.g. first diagnosis specific condition, initiation specific therapy) make part cohort. use OMOP CDM enables generation, review, approval transportable cohort definition across network previously mapped data sources. DARWIN EU Cohort Knowledge base (DECK short) compile transportable algorithm used identify cohort necessary conducting EMA-commissioned studies, including user specific medicinal product drug utilisation studies, people specific condition study descriptive epidemiology, people newly diagnosed specific health outcome study drug safety. DECK leverage existing knowledge compiled OHDSI community, previous EHDEN studies, previous studies, including EMA-commissioned tenders. existing preliminary version DECK collates large number clinical definition previously produced using previous studies. possible and/or necessary, DARWIN EU study leverage validated algorithm DECK. cumulative knowledge generated using DECK accelerate study conducted Years 3-5, also maximise reproducibility research re-using exact documented variation algorithm event time. Last Updated: 19 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Studies Studies DARWIN EU Coordination Centre implement necessary service generate reliable evidence real world data EU Regulatory network. Initially DARWIN EU provide service EMA National Competent Authorities (NCAs) Member States. network expands, DARWIN EU may perform study requested EMA behalf third party EU level health agency (e.g. European Centre Disease Prevention Control (ECDC), health technology assessment body payers. question raised partner EU Regulatory Network requiring additional evidence support regulatory decision-making, EMA frame research question evaluate, consultation Coordination Centre, relevance feasibility interrogating network. study, Coordination Centre develop study protocol, identify appropriate data source specific question, obtain EMA approval perform conduct study data partners. Following local governance procedure data partner need obtain mandatory institutional, IRB, and/or ethic approval. data partner receive run code database provide aggregated result Coordination Centre. Coordination Centre check quality study data received data partner perform additional data analysis step interpretation. Coordination Centre compile results, responsible draft study report submit report EMA approval. study DARWIN EU deliver grouped anticipated level complexity frequency: Category Description Off-The-Shelf Studies mainly characterisation question executed generic protocol. includes study disease epidemiology, example estimation prevalence incidence health outcome defined time period population groups, drug utilization study population patient level. Complex Studies study requiring development customisation specific study designs, protocols, analytics phenotypes. includes study safety effectiveness medicine vaccines. Routine Repeated Analyses Routine analysis based Off-The-Shelf Complex Studies (see above), repeated pre-specified regularity (e.g. yearly) Complex Studies Studies cannot rely electronic health care databases, require complex and/or novel methodological work study executed DARWIN EU Coordination Center registered . up-to-date list studies, search term DARWIN EU 'title study' field. list updated monthly basis. Status Type EU PAS Register number Official Title Last Updated Finalised off-the-shelf EUPAS50789 21/03/2024 Finalised off-the-shelf EUPAS103381 21/03/2024 Finalised complex EUPAS103936 21/03/2024 Finalised off-the-shelf EUPAS50800 21/03/2024 Ongoing off-the-shelf EUPAS105033 21/03/2024 Ongoing off-the-shelf EUPAS105641 21/03/2024 Ongoing complex EUPAS106679 06/03/2024 Ongoing off-the-shelf EUPAS106052 06/03/2024 Ongoing off-the-shelf EUPAS105644 21/03/2024 Ongoing off-the-shelf EUPAS106798 21/03/2024 Ongoing off-the-shelf EUPAS106436 21/03/2024 Ongoing off-the-shelf EUPAS106685 21/03/2024 Ongoing off-the-shelf EUPAS107708 21/03/2024 Ongoing off-the-shelf EUPAS107650 21/03/2024 Ongoing Complex EUPAS107615 21/03/2024 Ongoing off-the-shelf EUPAS107454 21/03/2024 Ongoing off-the-shelf EUPAS107932 21/03/2024 Last Updated: 24 March 2024 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data FAQs General General information DARWIN EU found menu. FAQs receive. EMA responsible providing leadership direction, setting standard DARWIN EU, contracting, instructing overseeing Coordination Centre monitoring performance. overall operation DARWIN EU overseen Management Pillar guidance Advisory Boards. board composed Scientific Advisory Board, Ethical Advisory Board, Data Source Prioritisation Committee. initiative also receives oversight DARWIN EU Advisory Board EMA, read . present, DARWIN EU CC provides service EMA National Competent Authorities (NCAs) Member States, therefore receives study request EMA behalf organisations. network expands, DARWIN EU may perform study requested EMA behalf third party EU level health agency (e.g. European Centre Disease Prevention Control (ECDC), health technology assessment body payers. read DARWIN EU work deliver study described Catalogue Standard Data Analyses. categorised Off-the-shelf, Complex, Complex Routine Repeated. read Studies published European Union Electronic Register Post-Authorisation Studies (EU PAS Register), access up-to-date list study DARWIN EU ha produced, search term DARWIN EU 'Title study' field. Otherwise, check updated list study website following organisation contribute establishment operational phase Coordination Centre: Fore information see . present, necessity add additional subcontractor organisation help deliver requested services. Erasmus University Medical Centre current contractor, subcontractor already added tendering process. get touch Coordination Centre email: email address protected spambots. need JavaScript enabled view it.or . Joining Network interested joining network, read process . FAQs process. No. considered candidate DP, first step submit Expression Interest. Yes, unless duly justified, case appropriate justification included. information contained EoI primarily used purpose evaluating candidacy formally become DARWIN EU Data Partner. access associated Data Protection Notice . Additionally, providing consent response specific question EoI form, potential DP agree EoI information used populate EU Metadata Catalogue, EMA initiative help improve data discoverability transparency. Catalogue intended public use, read associated Data Protection Notice No, continuously open call, please bear mind cut-off date (30th April, 31st October) review selection. No. CC may contact clarify certain aspect datasets EoI, invite initiate formal onboarding process. latter successfully completed agreement signed, DARWIN EU DP. onboarding process consists several quality technical check ensure readiness DARWIN EU studies, plus explanation term condition participation agreement legal provision apply relationship CC. duration vary 1 2 months, ordinarily. No. onboarding process ha successfully completed agreement CC ha signed. question listed above, get touch Coordination Centre email. Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Contact DARWIN EU Coordination Centre represented Department Medical Informatics Erasmus MC Route Description: Fields marked * required Type Question* Please select one General Question Open Call Expression Interest Data Protection Name* Email* Subject* Message* Consent* consent[] hereby give consent store process information provided form. Data Protection Notice* data_protection_notice[] hereby accept Enter captcha security code Send Email Send Email Reset PUBLIC TRANSPORT Metro A,B,C Alight Dijkzigt station follow sign Erasmus MC. Bus 44 Alight Dijkzigt station follow sign Erasmus MC. Tram 8 Alight Kievietslaan station. Enter Westzeedijk parking garage. Car direct vicinity Erasmus MC follow sign parking garages. Parking Westzeedijk Westzeedijk 361 3015 AA Rotterdam Parking Wytemaweg Wytemaweg 12 3015 CN Rotterdam Route Description Coordination Center hosted Department Medical Informatics 26th floor Na-Building. Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutCoordination Centre Coordination Centre EMA working Erasmus University Medical Center Rotterdam to: establish theDARWIN EUCoordination Centre, support work build distributed data network; conduct scientific study answer research question supporting regulatory decision-making EMA's scientific committee ; maintain catalogue real world data source use regulatory context metadata. DARWIN EU Coordination Centre key user future . contract establish Coordination Centre wa awarded Erasmus University Medical Center Rotterdam following call tender service provider published June 2021. group Department Medical Informatics leading Establishment Operational Phase DARWIN EU Coordination Centre. Organisational Structure DARWIN EU CC exists run study within data partner network, overseen Study Network Operations pillars, respectively. pillar able execute study onboard Data Partners using tool (such code protocols) created Development pillar within infrastructure ha created Technology pillar. Technology pillar also responsible producing necessary project resources, website service desk. overall operation DARWIN EU overseen Management pillar guidance Advisory Boards. Leadership Erasmus MC Executive Director Technology Pillar Lead Erasmus MC, Oxford University Deputy Director Development Pillar Lead Erasmus MC Deputy Director Study Operations Pillar Lead Synapse Research Management Partners Management Pillar Lead Erasmus MC Network Operations Pillar Lead Additional Members core team , Development Pillar Co-lead , MSc, Analytics Team Co-lead , Study Operations Co-lead , Technology Pillar Co-lead , Management Pillar Co-lead , Management Team Lead addition, large team data scientists, epidemiologist programmer working Coordination Centre Erasmus MC subcontractors. Contributing Organisations Organisation: Department Medical Informatics, Erasmus MC Description: Erasmus University Medical Center largest eight university medical center Netherlands. Department Medical Informatics, chaired Prof. dr. ir. Peter Rijnbeek, interdisciplinary research group within Erasmus MC study new method acquiring, representing, processing, managing data knowledge health care biomedical science ha developed land marking infrastructure software distributed analysis electronic health records. Health Data Science research line Prof. Rijnbeek leading , (EHDEN). mission group produce clinically actionable insight observational health data enabling data-driven healthcare. Improved interoperability data necessary pre-requisite mission. Learn Organisation: Clinical Investigation Translational Science, NDORMS, University Oxford Description: Clinical Investigation Translational Science division Botnar Research Centre (NDORMS, University Oxford) includes Clinical Trial Design Medical Statistics Health Data Science sections. Health Data Science section, led Prof Daniel Prieto-Alhambra, includes multidisciplinary team 30 staff student expertise data sciences, engineering, epidemiology, real world evidence. Learn at: Organisation: Synapse Research Management Partners Description: Synapse firm specialized high quality management complex research development project biomedical sector. Synapse partner national international organisations, public private (pharmaceutical biotechnology companies, research institutes, academia, hospitals, etc.). Synapse ha track record research project highly innovative (open innovation, public private partnerships), large (with several million Euros funding), distributed (built collaboration several institutions) internationally oriented (with broad expertise project funded European Commission). Learn . Organisation: Description: IQVIA leading global provider advanced analytics, technology solutions, clinical research service health sector across globe. IQVIA creates intelligent connection across aspect healthcare analytics, transformative technology, big data resource extensive domain expertise. IQVIA delivers powerful insight speed agility enabling life science industry customer accelerate clinical development commercialization innovative medical treatment enabling government ass improve public health population management, leading improved patient outcomes. approximately 86,000 employees, IQVIA conduct operation 100 countries. Learn . Organisation: Hyve Description: Hyve company provides professional service open source software. specialize field cancer genomics, translational data warehousing, real world data analytics research data management. customer include majority top 20 pharmaceutical companies, major academic medical center U.S. Europe well biobanks, registry patient organization throughout world. Learn Organisation: Odysseus Data Services, Inc. Description: Odysseus established real-world evidence (RWE) solution provider enabling standardized systematic analytics observational data scale. Odysseus providing customer Software, Data Engineering Data Science solution supporting large-scale RWE generation. Odysseus active OHDSI contributor multiple key initiative working groups, including design development OHDSI platform ATLAS/WebAPI, ARACHNE ATHENA, OMOP CDM standards, curating maintaining OMOP standard vocabulary well development OHDSI analytical method (HADES) OHDSI distributed network research. Odysseus created ARACHNE platform goal linking multiple distributed life science healthcare organization single network enable standardized federated analytics observational data. Learn Data Partners CC ha set agreement growing list Data Partners create distributed network data sources. information Data Partners found page. Last Updated: 12 May 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutWho Involved? involved? DARWIN EU ha multiple actors: , , , . Data Partners DARWIN EU collaborates data partner help generate real-world evidence used scientific evaluation regulatory decision-making. Data partner partner access raw data in-house remotely, ownership, public contract, third-party agreement commercial license. Data partner enable DARWIN EU use data scientific study executing analytic packages, provide analysis result DARWIN EU Coordination Centre, accordance data protection governancerules. information see page. Coordination Centre ha key function DARWIN EU. CC provides structure developing managing network data partners, including training process study methods, evaluating eligibility performing studies, monitoring data quality. CC also responsible implementing operating step , feasibility request study final delivery study report EMA, result integrated within EU regulatory decision making process. addition, Coordination Centre responsible methodological development DARWIN EU, directed instructed EMA, interact relevant initiatives. Erasmus University Medical Center Rotterdam wa selected contractor public tendering procedure published June 2021 setup Coordination Centre EMA. information see page. European Medicines Agency responsible providing leadership direction, setting standard DARWIN EU, contracting, instructing overseeing Coordination Centre monitoring performance. question raised EU Medicines Regulatory Network requiring additional evidence support regulatory decision-making, EMA coordinate definition research question define, requesting body, study objective possible study design option study population, exposures, outcome statistical measures. information communicated Cordination Centre feasibility assessment. Based feasibility assessment, EMA, consultation Cordination Centre, decide relevance conducting study, specify eligibility criterion database included, identify relevant database define evidentiary standard applied study (e.g., data quality). EMA process result analysis report specific studies, feeding result decision-making, appropriate. support establishment DARWIN EU, ha set EMA. EU Medicines Regulatory Network EU Medicines Regulatory Network includes EMA (encompassing scientific committee working parties), national competent authority (NCAs) Member States European Economic Area (EEA) European Commission. operation DARWIN EU, need additional real-world evidence identified within EU Medicines Regulatory Network support regulatory activity submitted discussed EMA. Organisations Interactions EMA organisations, institution project take place improve infrastructure, methodological standard operational process DARWIN EU network. interaction could take place with, example: (EHDS), DARWIN EU key user need fully integrated use service provided EHDS; ongoing EU national project scope DARWIN EU relevant quality, transformation, maintenance analysis real-world datasets, including European networking initiative (EHDEN) project, European platform registry European Reference Networks (ERNs), ha established registry platform rare diseases; (ENCePP) network, integration continuously updating good methodological practice pharmacoepidemiology, identification data source registration studies; regulatory authority third countries, learn experience integrate learning governance methodological aspects. Last Updated: 26 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutPrinciples & Policies Principles & Policies Table content Data Protection DARWIN EU Coordination Center (CC) executes study distributed data network using federated approach analytical code shared data partner aggregated study result shared CC. privacy-by-design approach additional measure added, example minimum cell count, comply local governance rules. data partner setup includes information procedure. information study execution found . latest version Record Processing Activities (ROPA) found below. information also see . Cookie Policy DARWIN EU Coordination Center website,we use cooky enablethe technical functioning thiswebsite.In addition, consent it, use cooky collect browsing experience website. enables u tocollect anonymous statistic help u improve website services. information see website. Conflict Interest study analysis conducted DARWIN EU shall conducted accordance principle scientific independence, set According ENCePP, scientific independence mean that: primary purpose study shall generate evidence potential scientific public health importance promote use medicinal product specific outcome; design research shall aim minimising potential bias; financial, commercial, institutional, personal interest particular outcome study (i.e., result interpretation) level organisation(s) initiating funding study coordinating study entity and/or researcher(s) conducting study, shall influence decision scientific aspect study direction, including data collection analysis, interpretation dissemination study results. relevant, definition principle set shall also applied. Related content Related document List item First published: 18/03/2023 EMA/51069/2023 List item First published: 18/03/2023 Last Updated: 27 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data AboutWebinars DARWIN EU: multi-stakeholder information webinar Date: 24-02-2022 Location:Online, 10:30 - 12:00 Amsterdam time (CET) Event summary EMA organised multi-stakeholder information webinar to: introduce DARWIN EU recently appointed Coordination Centre; highlight opportunity collaboration answer stakeholder questions. Video recording Documents Last Updated: 10 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Legal Notice Legal Notice Table content Information onThe DARWIN EU website subject disclaimer copyright limited reproduction notices. Disclaimer website managed Erasmus University Medical Center Rotterdam (hereinafter "Coordination Centre" "CC") behalf European Medicines Agency (hereinafter "EMA") contract signed CC EMA (see Official Journal ). Coordination Centre maintains website enhancepublic accessto information activity performing behalf European Medicines Agency. CC's goal keep information material timely accurate. error brought attention, CC try correct them. CC EMA acceptno responsibility liabilitywhatsoever (including, limited to, direct consequential loss damage might occur and/or third party) arising of, connection with, information site, including information relating document may publish link to. particular, CC EMA shall held harmless from, indemnified costs, proceedings, claims, expense liability whatsoever arising breach legal natural person result representation warranty providing misrepresentation. information CC provides is: general nature intended address specific circumstance particular individual entity; necessarily comprehensive, complete, accurate date; sometimes linked external site CC ha control CC assumes responsibility; amounting professional legal advice. CC's goal minimise disruption caused technical errors. However, data information website may created structured file format error-free. CC EMA cannot guarantee service interrupted otherwise affected problems. CC EMA accept responsibility whatsoever regard problem incurred result using website. Copyright limited reproduction notice appearance content webpage subject copyrights, whether EMA third party (" 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency.") Information document made available DARWIN EU webpage public may reproduced and/or distributed, totally part, irrespective mean and/or format used, provided DARWIN EUwebsite always acknowledged source material. acknowledgement must included copy material. Citations may made material without prior permission, provided source always acknowledged. However, document copyright vest third party, permission reproduction must obtained copyright holder. DARWIN EU Trademark Logo DARWIN EU European Union figurative trademark owned European Medicines Agency (EUTM no. 018305237). Use trademark prohibited without prior written permission EMA. Citing website cite material DARWIN EU website, please list URL, month year accessed it, using following format: DARWIN EU: Expression Interest(XLSX/188KB), https://darwin-eu.org/data/Expression.of.Interest.form.v.03a.xlsx, 27-03-2023 Links website CC encourages organisation individual create link website following conditions: Links must used defamatory context. Linked information must changed way. Linked information darwin-eu.org displayed manner suggests endorsement commercial product service. Linked information darwin-eu.org displayed alongside advertising. Last Updated: 27 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency. Data Cookie Policy Cookie Policy Table content make website work properly, DARWIN EU Coordination Centre (CC) place small data file called cooky device. Website visitor decide whether tracked cookies. delete cooky time. cooky cookie small piece ofdatathat website store visitor computer mobile device. DARWIN EU Website theDARWIN EU Coordination Centreuses cooky enablethe technical functioning thiswebsite.In addition, consent it, use cooky collect browsing experience website. enables u tocollectanonymous statisticsto help u improve website services. Different type cookiesexist: First-party cooky set website visiting website read them. website might use first-party cooky external service analyse people use site, JRealtime Analytics (see below). Third-party cooky set stored different website manner outsidethe control site visiting. Session cooky temporarily saved web browser enable website track navigation, treated new user every time go page page. aredeleted automatically close browser. Persistent cooky saved computer longer deleted automatically close browser. JRealtime Analytics cooky JRealtime Analytics tool running server monitor browsing experience website. use evaluate website's effectiveness efficiency. solely based native session cookie Joomlato collect statistics. DARWIN EU Coordination Centreretains full control data collected native cookie, storing dataon server. platform enables protection personal data usersthanks feature de-identification ofIP addresses. Consent collecting browsing experience register yourbrowsing experience using cooky areenabled open page. visit website, banner appears givesyou option accept eitherallcookies essential cookies. accept essential cookies, stop JRealtime Analytics. accept cookies, enable JRealtime Analytics. make selection continue browse website, cooky areenabled default. Choosing accept essential cooky doe affect navigation experience website. decide withdraw give consent enabling cooky time. cookie popup remain visible bottom webpage change preference. Data protection JRealtime Analytics JRealtime Analytics us cookiesto track following information visitors: IP address (de-identified) Location(country, region, city, approximate latitude longitude) Date time visit Title page viewed URL page viewed URL page wa viewed prior current page Time visitor'slocal time zone Duration visit page Links another websitethat clicked Time webpage generated server downloaded visitor Browser type (Safari, Chrome, etc.) Operating system (Window, Mac, etc.) Device type (Desktop, Laptop, etc.) Restricted access information Onlyauthorised staff DARWIN EU Coordination Centre authorised access theanalytical report generated JRealtime Analytics. report graphical representation item described above, example visitor per country pie chart operating systems. access reportsthrough administrative portal DARWIN EU Website. Masking IP address JRealtime Analytics us anIP de-identification mechanismto automatically maska portion visitor's IP address. Thiseffectively makesit impossible identify particularvisitor using IP address. statistical purposes, city country origin determined full IP address, stored aggregated anonymisation mask applied. Visitor log DARWIN EU Coordination Centre store anonymised aggregated data indefinite period analysis purposes. cooky website contains user-input cookies, aresession cookies. support user feedback featurethatallows youto rate usefulness website's page tell u more. website doe use third-party cooky stored different website, butit doe contain link audiovisual content website thatmay use cookies. viewthis content, need accept thespecific term condition external website, includes cookie policies. CC ha control cookie policy external websites. view content, external provider install anythird-party cooky device. Details thecookie policy websitesare provided cookie notice pages. 'Do track' option 'Do track'is browser function prevents website trackingvisitors. enabled 'do track' option browser, JRealtime Analytics process browsing experience website. number browser 'do track' option: Related content Last Updated: 29 March 2023 Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network. 2024 - 2023 European Medicines Agency. right reserved. Certain part licensed condition European Medicines Agency.